Oncolytic virotherapy: new weapon for breast cancer treatment.
BC
OVs
immunotherapy
Journal
Ecancermedicalscience
ISSN: 1754-6605
Titre abrégé: Ecancermedicalscience
Pays: England
ID NLM: 101392236
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
06
2020
entrez:
12
2
2021
pubmed:
13
2
2021
medline:
13
2
2021
Statut:
epublish
Résumé
The recent introduction of viruses as a weapon against cancer can be regarded as one of the most intriguing approaches in the context of precision medicine. The role of immune checkpoint inhibitors has been extensively studied in early and advanced cancer stages, with extraordinary results. Although there is a good tolerability profile, especially when compared with conventional chemotherapy, severe immune-related adverse events have emerged as a potential limitation. Moreover, there are still treatment-resistant cases and thus further treatment options need to be implemented. Several
Identifiants
pubmed: 33574894
doi: 10.3332/ecancer.2020.1149
pii: can-14-1149
pmc: PMC7864690
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1149Informations de copyright
© the authors; licensee ecancermedicalscience.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Nat Commun. 2012;3:1282
pubmed: 23250412
Virus Res. 2014 May 12;184:71-81
pubmed: 24589707
Cancers (Basel). 2018 Jun 15;10(6):
pubmed: 29914097
Gene Ther. 2009 May;16(5):689-99
pubmed: 19282847
Cell Immunol. 2020 Feb;348:104041
pubmed: 31983398
Breast Cancer Res. 2012 May 22;14(3):R81
pubmed: 22616919
J Natl Cancer Inst. 2006 Mar 1;98(5):298-300
pubmed: 16507823
PLoS Pathog. 2009 Jul;5(7):e1000384
pubmed: 19649323
Int J Mol Sci. 2016 Dec 02;17(12):
pubmed: 27918449
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
J Clin Invest. 2015 Sep;125(9):3356-64
pubmed: 26168215
Clin Cancer Res. 2013 May 15;19(10):2734-44
pubmed: 23493351
Cancer Lett. 2013 Jan 1;328(1):95-103
pubmed: 23000515
Cancer Gene Ther. 2014 Sep;21(9):373-80
pubmed: 25145311
Science. 1991 May 10;252(5007):854-6
pubmed: 1851332
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Clin Cancer Res. 2016 Apr 15;22(8):1865-74
pubmed: 27084740
Nat Cell Biol. 2001 Aug;3(8):745-50
pubmed: 11483960
J Clin Oncol. 2015 Sep 1;33(25):2780-8
pubmed: 26014293
Mol Ther. 2010 Aug;18(8):1440-9
pubmed: 20551913
Genes Dis. 2018 May 17;5(3):194-203
pubmed: 30320184
Nat Med. 2007 Oct;13(10):1155-9
pubmed: 17917664
Clin Cancer Res. 2011 Feb 15;17(4):888-95
pubmed: 21304001
Oncotarget. 2017 Dec 13;9(7):7398-7410
pubmed: 29484119
Breast Cancer Res Treat. 2018 Dec;172(3):713-723
pubmed: 30173296
Mol Diagn Ther. 2017 Oct;21(5):493-510
pubmed: 28477149
Mol Ther. 2010 Aug;18(8):1430-9
pubmed: 20551919
Invest New Drugs. 2010 Oct;28(5):641-9
pubmed: 19572105
Clin Cancer Res. 2006 Apr 15;12(8):2555-62
pubmed: 16638865
J Immunol. 2012 Feb 15;188(4):1592-9
pubmed: 22231700
Gac Med Mex. 2017 Mar - Apr;153(2):229-237
pubmed: 28474709
Nat Rev Immunol. 2003 Dec;3(12):984-93
pubmed: 14647480
Biomaterials. 2016 May;89:56-66
pubmed: 26950165
Oncotarget. 2016 Mar 1;7(9):10133-52
pubmed: 26840086
Clin Cancer Res. 2008 Jan 1;14(1):259-69
pubmed: 18172278
Oncotarget. 2016 Nov 29;7(48):79828-79841
pubmed: 27806313
Tumour Biol. 2016 Apr;37(4):4251-61
pubmed: 26779629
Breast Cancer Res. 2015 Sep 04;17:124
pubmed: 26341640
Nat Med. 2019 Jun;25(6):920-928
pubmed: 31086347
Cancer Res. 2001 Oct 15;61(20):7464-72
pubmed: 11606381
Eur J Pharmacol. 2018 Oct 15;837:117-126
pubmed: 30179611
Mol Ther. 2015 Jan;23(1):202-14
pubmed: 25292189
BMC Med. 2019 May 9;17(1):90
pubmed: 31068190
Mol Pharm. 2019 Feb 4;16(2):779-785
pubmed: 30604617
Mol Ther. 2004 Apr;9(4):489-95
pubmed: 15093179
Sci Rep. 2019 Sep 30;9(1):13999
pubmed: 31570732
J Exp Med. 1925 Sep 30;42(4):523-37
pubmed: 19869072
Mol Ther. 2007 Jan;15(1):123-30
pubmed: 17164783
J Oncol. 2019 Nov 18;2019:5879616
pubmed: 31827511
Stem Cells. 2003;21(4):389-404
pubmed: 12832693
Nat Commun. 2020 Mar 13;11(1):1395
pubmed: 32170083
FEBS Lett. 2014 Jan 21;588(2):368-76
pubmed: 24161671
Int J Cancer. 2015 Apr 1;136(7):1718-30
pubmed: 25156870
Front Oncol. 2020 Mar 24;10:384
pubmed: 32266155
Clin Cancer Res. 2005 Jul 1;11(13):4889-97
pubmed: 16000587
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):53-60
pubmed: 14734451
J Immunother. 2000 Sep-Oct;23(5):570-80
pubmed: 11001550
Nat Rev Immunol. 2009 May;9(5):353-63
pubmed: 19365408
Front Oncol. 2014 Jun 11;4:145
pubmed: 24967214
Crit Rev Oncol Hematol. 2008 Apr;66(1):1-9
pubmed: 17913510
Nature. 2009 Jan 22;457(7228):485-9
pubmed: 19043403
Breast Cancer Res Treat. 2009 Jan;113(1):21-30
pubmed: 18256929
Sci Transl Med. 2014 Mar 5;6(226):226ra32
pubmed: 24598590
Biomolecules. 2020 Mar 25;10(4):
pubmed: 32218180
J Immunother Cancer. 2018 Dec 4;6(1):140
pubmed: 30514385
Cancer. 1949 May;2(3):525-34
pubmed: 18131412
J Cell Biochem. 2017 Sep;118(9):2484-2501
pubmed: 28106295
Front Immunol. 2015 Apr 24;6:187
pubmed: 25964783
Ann Surg Oncol. 2006 Aug;13(8):1078-84
pubmed: 16865590
Cancer Gene Ther. 2006 Nov;13(11):975-92
pubmed: 16604059
Cancer Gene Ther. 2001 Mar;8(3):168-75
pubmed: 11332987
Biosci Rep. 2019 Jul 23;39(7):
pubmed: 31278126
Cancer Res. 2010 Apr 15;70(8):3052-61
pubmed: 20388795
Front Mol Biosci. 2019 Sep 27;6:90
pubmed: 31612140
Hum Pathol. 2016 Jan;47(1):52-63
pubmed: 26527522
Breast Cancer Res. 2011;13(6):R126
pubmed: 22151962
Oncogene. 2019 Jun;38(26):5158-5173
pubmed: 30872795
Cancer Lett. 2020 Jun 1;479:42-53
pubmed: 32200038
Breast Cancer Res. 2007;9(4):212
pubmed: 17705880
Sci Transl Med. 2017 Mar 15;9(381):
pubmed: 28298418
Cancer Gene Ther. 2007 Nov;14(11):885-93
pubmed: 17704755
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
Viruses. 2019 Jun 06;11(6):
pubmed: 31174402
AMA Arch Derm Syphilol. 1950 Nov;62(5):694-5
pubmed: 14770525
J Exp Med. 2010 Oct 25;207(11):2469-77
pubmed: 20921286
Oncol Lett. 2019 May;17(5):4155-4161
pubmed: 30944610
Sci Transl Med. 2018 Jan 3;10(422):
pubmed: 29298869
Cell. 2017 Sep 7;170(6):1109-1119.e10
pubmed: 28886381
Mol Ther Oncolytics. 2019 Feb 23;12:259-262
pubmed: 33072862
Breast Cancer Res Treat. 2018 Jan;167(2):485-493
pubmed: 29027598
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
J Surg Oncol. 2004 Jan;85(1):42-7
pubmed: 14696086
Drugs. 2016 Jan;76(1):147-54
pubmed: 26620366
Clin Cancer Res. 2006 Nov 15;12(22):6737-47
pubmed: 17121894
Cytokine. 2018 May;105:63-72
pubmed: 29459345
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Int Immunol. 2016 Aug;28(8):401-9
pubmed: 27160722
Cancer Gene Ther. 2015 Sep;22(9):438-44
pubmed: 26272026
J Immunother Cancer. 2019 Jan 28;7(1):20
pubmed: 30691536
J Virol. 2011 Jun;85(12):6015-23
pubmed: 21471241
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7
pubmed: 22451913
Clin Cancer Res. 2015 Aug 15;21(16):3597-601
pubmed: 26116271
Breast Cancer Res Treat. 2010 Aug;122(3):745-54
pubmed: 19894113
Cell Mol Life Sci. 2011 Aug;68(16):2667-88
pubmed: 21560073
Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13109-13
pubmed: 23878230
Front Pharmacol. 2017 Jan 12;7:533
pubmed: 28127287
Nat Rev Cancer. 2016 Feb;16(2):121-6
pubmed: 26822578
J Biol Chem. 2016 Jan 15;291(3):1251-66
pubmed: 26553869
Nat Rev Drug Discov. 2015 Sep;14(9):642-62
pubmed: 26323545